FMTX News and Press, Forma Therapeutics Holdings Inc. From 04/29/22

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release first quarter 2022 financial results Friday, May 6, 2022...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Lone Pine Capital’s 13F portfolio value decreased from $29.68B to $24.41B. The number of positions decreased from 39 to 29. They increased Amazon, RH, NetEase, Confluent, and Marqeta while reducing Block and dropping Moderna and Meta Platforms. The top three positions are A...

Forma Therapeutics Holdings, Inc. (FMTX) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Mario Corso – Senior Director of Investor Relations Frank Lee – President and Chief Executive Officer Patrick Kelly – Senior Vice President, Chief Medic...

Forma Therapeutics press release (NASDAQ:FMTX): Q4 GAAP EPS of -$1.06 misses by $0.10.  Cash, cash equivalents and marketable securities were $490.3 million as of December 31, 2021, as compared to $645.6 million as of December 31, 2020. For further details see: Forma Therapeutics G...

Clinical stage programs focused on rare hematologic diseases and cancers Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III trial enrolling Ini...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2021 financial results Tuesd...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers , today announced that it will present at the virtual 11 th Annual SVB Leerink Global ...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that Arturo Molina, M.D., M.S., F.A.C.P., has been elected to serve on the compan...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers , today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conf...